From the National Post:
Canada’s pharmaceutical industry and the European Union have been quietly lobbying for changes that could give brand-name drugs several years more patent protection here — and potentially add hundreds of millions of dollars to Canadian medication costs annually.
The EU has reportedly proposed the measures be included in a landmark free-trade agreement now being negotiated between the jurisdictions, with the fifth round starting last week in Ottawa.
The changes would delay the entry of cheaper, generic copies of medication onto the market, but brand-name companies and some provinces say the measures are needed to restore fairness to the complex patent system, and generate more drug research in Canada. ...more
Wednesday, October 27, 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment